Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer

European Journal of Cancer

Volumn 40, Issue 5, 2004, Pages 701-706

  Nuver, J ^a   Smit, A J ^a   Sleijfer, D Th ^a   Van Gessel, A I ^a   Van Roon, A M ^a   Van Der Meer, J ^a   Van Den Berg, M P ^a   Burgerhof, J G M ^a   Hoekstra, H J ^a   Sluiter, W J ^a   Gietema, J A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Albuminuria; Arteriosclerosis; Endothelium; Fibrinolysis; Inflammation; Plasminogen activator inhibitors; Testicular neoplasms; Von Willebrand Factor

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM INJURY; FIBRINOLYSIS; FOLLOW UP; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METASTASIS; MICROALBUMINURIA; ORCHIECTOMY; PREVALENCE; PRIORITY JOURNAL; TESTIS CANCER;

ADULT; AGED; ALBUMINURIA; ANTINEOPLASTIC AGENTS; ARTERIOSCLEROSIS; BLOOD COAGULATION FACTORS; C-REACTIVE PROTEIN; CISPLATIN; CROSS-SECTIONAL STUDIES; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; TESTICULAR NEOPLASMS;

EID: 12144289390     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.12.012     Document Type: Article

References (23)

1. Gietema J.A., Sleijfer D.Th., Willemse P.H.B.et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann. Intern. Med. 116:1992;709-715.
2. Bokemeyer C., Berger C.C., Kuczyk M.A., Schmoll H.J. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J. Clin. Oncol. 14:1996;2923-2932.
3. Nord C., Fossa S.D., Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br. J. Cancer. 88:2003;36-41.
4. Meinardi M.T., Gietema J.A., van der Graaf W.T.et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18:2000;1725-1732.
5. Huddart R.A., Norman A., Shahidi M.et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21:2003;1513-1523.
6. Shi Y., Inoue S., Shinozaki R., Fukue K., Kougo T. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn. J. Cancer Res. 89:1998;757-767.
7. Dirix L.Y., Libura M., Libura J., Vermeulen P.B., De Bruijn E.A., van Oosterom A.T. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs. 8:1997;859-868.
8. Diercks G.F., Stroes E.S., van Boven A.J.et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. Atherosclerosis. 163:2002;121-126.
9. Hillege H.L., Fidler V., Diercks G.F.et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 106:2002;1777-1782.
10. Gao S., Hui S.L., Hall K.S., Hendrie H.C. Estimating disease prevalence from two-phase surveys with non-response at the second phase. Stat. Med. 19:2000;2101-2114.
11. O'Rourke M. Mechanical principles in arterial disease. Hypertension. 26:1995;2-9.
12. Stehouwer C.D., Yudkin J.S., Fioretto P., Nosadini R. How heterogeneous is microalbuminuria in diabetes mellitus? The case for 'benign' and 'malignant' microalbuminuria. Nephrol. Dial. Transplant. 13:1998;2751-2754.
13. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 94:1996;2057-2063.
14. Thogersen A.M., Jansson J.H., Boman K.et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. evidence for the fibrinolytic system as an independent primary risk factor Circulation. 98:1998;2241-2247.
15. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979.
16. Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease. is there a link? Lancet. 350:1997;430-436.
17. Haffner S.M., Karhapaa P., Mykkanen L., Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 43:1994;212-219.
18. Rosano G.M., Leonardo F., Pagnotta P.et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 99:1999;1666-1670.
19. Nord C., Bjoro T., Ellingsen D.et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur. Urol. 44:2003;322-328.
20. Montauban van Swijndregt A.D., De Lange E.E., De Groot E., Ackerstaff R.G. An in vivo evaluation of the reproducibility of intima-media thickness measurements of the carotid artery segments using B-mode ultrasound. Ultrasound Med. Biol. 25:1999;323-330.
21. Urbina E.M., Srinivasan S.R., Tang R., Bond M.G., Kieltyka L., Berenson G.S. Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (The Bogalusa Heart Study). Am. J. Cardiol. 90:2002;953-958.
22. Cortellaro M., Baldassarre D., Cofrancesco E.et al. Relation between hemostatic variables and increase of common carotid intima-media thickness in patients with peripheral arterial disease. Stroke. 27:1996;450-454.
23. Cao J.J., Thach C., Manolio T.A.et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly. the Cardiovascular Health Study Circulation. 108:2003;166-170.